• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Emirates slams Boeing over 777X jet delays

October 5, 2021 by David Barret Leave a Comment

October 5, 2021

By Tim Hepher

Boston (Reuters) -The head of Dubai airline Emirates piled pressure on planemaker Boeing on Tuesday over delays to its 777X jetliner, warning that the uncertainty would cause significant disruption for one of the world’s biggest carriers.

Emirates President Tim Clark said he wanted “another grown-up conversation” with the U.S. planemaker over the timing of the twin-engined jumbo, which is running at least two-and-a-half years behind its originally planned arrival of June 2020.

“We work to precision. I struggle with others who can’t get that,” Clark told reporters shortly before he was due to meet Boeing leaders on the sidelines of an airline industry summit.

Clark, an airline industry veteran who was closely involved in the development of the current 777-300ER model, has lambasted Boeing this year over repeated delays to its 777X.

Boeing did not immediately respond to a request for comment.

The company has previously said it plans to start delivering the new, larger version of the 777 wide-body jet by late 2023, three years later than originally planned, partly owing to a longer certification process after fatal 737 MAX jet crashes.

Clark, who was taking part in an International Air Transport Association meeting in Boston, emphasised that the uncertainty over Boeing’s progress with the programme would hamper his airline’s complex fleet plans which include Airbus jets.

Emirates, which has 126 777X jets on order, is a launch customer for the new aircraft that will replace the current 777 jets that are the backbone of its wide-body fleet.

Clark said that Emirates still did not know when the first 777-9 version of the twin-engine jumbo would arrive, nor whether the smaller 777-8 version would be built at all.

In May, Clark said Emirates would refuse delivery of 777X jets that did not meet contractual agreements. On Tuesday he said he would like industry contracts to be altered to make manufacturers more liable for the knock-on effects of delays.

Currently manufacturers are liable for product defects, not indirect “consequential damages” such as passenger compensation. Analysts say industrial suppliers are reluctant to take on commitments that create open exposure to airline operations.

In April the Gulf airline’s chairman said that some of the 126 777X jets ordered could be swapped for smaller Boeing 787 Dreamliners.

Emirates already revised its order for the 777X in 2019, cancelling orders for 24 of the jets as part of a deal that saw it agree to buy 30 Dreamliners.

Asked on Tuesday whether Emirates could swap more 777X planes for the smaller 787, Clark said much would depend on Boeing.

Turning to recovery, Clark said bookings had increased significantly to markets that are reopening after COVID-19.

“We’ve reduced the loss over this time last year by a significant percentage,” he said.

“With opening of borders, we’ve seen a major kick-in of income, of demand, so in the second half of the financial year, we’re looking to see a much greater improvement as to the first half,” he added.

“We still won’t be out of the woods … but going forward into the 2022-23 (April/March) financial year, I’m sure the business will really start to generate the cash that it needs and go profitable during the course of 2022-23, moderately so.”

Emirates is due to report first-half earnings next month.

(Reporting by Tim Hepher; Writing by Alexander Cornwell; Editing by David Goodman and Richard Pullin)

Source Link Emirates slams Boeing over 777X jet delays

David Barret
David Barret

Related posts:

  1. Mexico’s top court decriminalizes abortion in ‘watershed moment’
  2. SoftBank leads $680 million funding round in NFT fantasy soccer game Sorare
  3. Evergrande woes hit Japan’s toilet, air-conditioner and paint manufacturers
  4. ‘No Time to Die’ opens with $121 million in international box office sales

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • The World’s Biggest Frog Is A 3.3-Kilogram, Nest-Building Whopper With No Croak To Be Found
  • Interstellar Object 3I/ATLAS Has Slightly Changed Course And May Have Lost A Lot Of Mass, NASA Observations Show
  • “Behold The GARLIATH!”: Enormous “Living Fossil” Hauled From Mississippi Floodplains Stuns Scientists
  • We Finally Know How Life Exists In One Of The Most Inhospitable Places On Earth
  • World’s Largest Spider Web, Created By 111,000 Arachnids In A Cave, Is Big Enough To Catch A Whale
  • What Is A Horse Chestnut? A Crusty Remnant Of Evolution (That People Like To Feed Their Dogs)
  • First Evidence Of High “Forever Chemicals” In Urban Wild Mammals Reveals Australian Possums Contaminated With PFAS
  • Why Don’t You Have A Tail?
  • What Happens If Someone Actually Finds The Loch Ness Monster?
  • Golden Comet C/2025 K1 (ATLAS) Is A Chemical Rarity – And It Should Have Been Destroyed!
  • Bat Species Not Seen In 55 Years Rediscovered And Filmed For First Time – Just Look At Those Ears
  • At Last, We May Finally Have A Way To Tell Female Dinosaurs From Males
  • Giraffes In North American Zoos Have Been Hybridizing – And That’s A Problem
  • Watch: Cosmic Fireworks As Comet Fragment Traveling Over 80,000 Kilometers Per Hour Explodes In The Air
  • Why Don’t Birds Die When They Sit On 400,000-Volt Power Lines?
  • On November 13, 2026, Voyager Will Reach One Full Light-Day Away From Earth
  • Why Don’t We Ride Zebras?
  • Interstellar Object 3I/ATLAS Changed Color Again, And Shows Signs Of Non-Gravitational Acceleration
  • Record-Breaking Brightest Black Hole Flare Shines With The Light Of 10 Trillion Suns
  • The Feared Post-COVID “Disease Rebound” Of Rampaging Infections Never Really Happened
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version